Search research articles
Contact Us
Filters
Showing results (11-20 of 92) with videos related to
Page
of 10
Sort By:
Hepatology (Baltimore, Md.)
|
August 22, 2023
Prediction of outcomes in patients with acute variceal bleeding
Ian A Rowe
The Lancet. Gastroenterology & Hepatology
|
December 20, 2017
Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease
Ian A Rowe
Journal of Hepatology
|
November 10, 2015
Capitalising on improved rates of diagnosis of early hepatocellular carcinoma
Ian A Rowe, Morris Sherman
Clinical Medicine (London, England)
|
April 28, 2018
Surveillance for hepatocellular cancer
Anna Roskilly, Ian A Rowe
Journal of Hepatology
|
April 14, 2022
Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction
Ian A Rowe, Gennaro D'Amico
Hepatology (Baltimore, Md.)
|
January 19, 2017
What is the benefit of early follow-up after hospitalization for patients with cirrhosis?
Robert Driver, Ian A Rowe
Lancet (London, England)
|
November 30, 2018
Questions in the design of ANSWER
Ian A Rowe, Richard Parker
Gastroenterology
|
December 3, 2014
Liver biopsy for the selection of patients with nonalcoholic steatohepatitis for clinical trials
Ian A Rowe, Richard Parker
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 6, 2021
The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained
Ian A Rowe, Richard Parker
Nature Reviews. Gastroenterology & Hepatology
|
June 15, 2019
The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information
Ian A Rowe, Richard Parker
Page
of 10
Search research articles
Search
Showing results (11-20 of 92) with videos related to
Sort By:
Page
of 10
Hepatology (Baltimore, Md.)
|
August 22, 2023
Prediction of outcomes in patients with acute variceal bleeding
Ian A Rowe
The Lancet. Gastroenterology & Hepatology
|
December 20, 2017
Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease
Ian A Rowe
Journal of Hepatology
|
November 10, 2015
Capitalising on improved rates of diagnosis of early hepatocellular carcinoma
Ian A Rowe, Morris Sherman
Clinical Medicine (London, England)
|
April 28, 2018
Surveillance for hepatocellular cancer
Anna Roskilly, Ian A Rowe
Journal of Hepatology
|
April 14, 2022
Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction
Ian A Rowe, Gennaro D'Amico
Hepatology (Baltimore, Md.)
|
January 19, 2017
What is the benefit of early follow-up after hospitalization for patients with cirrhosis?
Robert Driver, Ian A Rowe
Lancet (London, England)
|
November 30, 2018
Questions in the design of ANSWER
Ian A Rowe, Richard Parker
Gastroenterology
|
December 3, 2014
Liver biopsy for the selection of patients with nonalcoholic steatohepatitis for clinical trials
Ian A Rowe, Richard Parker
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 6, 2021
The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained
Ian A Rowe, Richard Parker
Nature Reviews. Gastroenterology & Hepatology
|
June 15, 2019
The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information
Ian A Rowe, Richard Parker
Page
of 10